TY  - GEN
AU  - Nuñez, Olivier
AU  - Olmedo, Carmen
AU  - Moreno-Perez, David
AU  - Lorusso, Nicola
AU  - Fernández Martínez, Sergio
AU  - Pastor Villalba, Pedro Eliseo
AU  - Gutierrez, Ángeles
AU  - Alonso Garcia, Marcos
AU  - Latasa, Pello
AU  - Sancho, Rosa
AU  - Mendioroz, Jacobo
AU  - Martinez-Marcos, Montserrat
AU  - Muñoz Platón, Enriqueta
AU  - García Rivera, María Victoria
AU  - Pérez-Martínez, Olaia
AU  - Álvarez-Gil, Rosa
AU  - Rivas Wagner, Eva
AU  - López González-Coviella, Nieves
AU  - Zornoza, Matilde
AU  - Barranco Boada, María Isabel
AU  - Pacheco, M Del Carmen
AU  - Álvarez Río, Virginia
AU  - Fiol Jaume, Miguel
AU  - Morey Arance, Roxana
AU  - Adiego Sancho, Begoña
AU  - Mendez Diaz, Manuel
AU  - Batalla, Noa
AU  - Andreu, Cristina
AU  - Castilla, Jesús
AU  - Garcia-Cenoz, Manuel
AU  - Fernández Ibáñez, Ana
AU  - Huerta Huerta, Marta
AU  - Ibáñez Pérez, Ana Carmen
AU  - Berradre-Sáenz, Belén
AU  - Lamas, Joaquín
AU  - Hermoso, Luisa
AU  - Casado Cobo, Susana
AU  - Galán Cuesta, Manuel
AU  - Montenegro, Sara
AU  - Domínguez, María
AU  - Jarrin Vera, Inmaculada
AU  - Limia, Aurora
AU  - Pastor-Barriuso, Roberto
AU  - Monge Corella, Susana
AU  - Nirsevimab Effectiveness Study Collaborators
PY  - 2025
DO  - 10.2807/1560-7917.ES.2025.30.5.2400596
SN  - 1025-496X
UR  - https://hdl.handle.net/20.500.12105/26330
AB  - Background: Respiratory syncytial virus (RSV) causes substantial morbidity in infants < 1 year. In October 2023, Spain recommended the monoclonal antibody nirsevimab to all children born since 1 April 2023, at birth or as catch-up if born before...
LA  - eng
PB  - European Centre for Disease Prevention and Control (ECDC)
KW  - Nirsevimab
KW  - Effectiveness
KW  - Hospitalisation
KW  - Observational study
KW  - Respiratory syncytial virus
KW  - Antiviral Agents
KW  - Case-Control Studies
KW  - Female
KW  - Hospitalization
KW  - Humans
KW  - Infant
KW  - Infant, Newborn
KW  - Male
KW  - Palivizumab
KW  - Respiratory Syncytial Virus Infections
KW  - Respiratory Syncytial Virus, Human
KW  - Seasons
KW  - Spain
KW  - Vaccination
TI  - Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season
TY  - research article
ER  -